CN1221263C - 一种治疗痤疮的凝胶型药物组合物及其制备工艺 - Google Patents
一种治疗痤疮的凝胶型药物组合物及其制备工艺 Download PDFInfo
- Publication number
- CN1221263C CN1221263C CN 03132232 CN03132232A CN1221263C CN 1221263 C CN1221263 C CN 1221263C CN 03132232 CN03132232 CN 03132232 CN 03132232 A CN03132232 A CN 03132232A CN 1221263 C CN1221263 C CN 1221263C
- Authority
- CN
- China
- Prior art keywords
- gel
- vitamin
- carbomer
- kecuocryptone
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 238000001879 gelation Methods 0.000 title description 2
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960001631 carbomer Drugs 0.000 claims abstract description 21
- 229930183118 Tanshinone Natural products 0.000 claims abstract description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 10
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 10
- 239000011719 vitamin A Substances 0.000 claims abstract description 10
- 229940045997 vitamin a Drugs 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 9
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001082 trimethoprim Drugs 0.000 claims abstract description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical class CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 8
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 2
- 229940082484 carbomer-934 Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 230000035699 permeability Effects 0.000 abstract description 4
- 229960004756 ethanol Drugs 0.000 abstract description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 abstract 4
- 235000019441 ethanol Nutrition 0.000 abstract 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- -1 Acritamer 940 Chemical compound 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 150000000211 1-dodecanols Chemical class 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于中西药凝胶制剂，特别涉及克痤隐酮凝胶及其制备工艺。克痤隐酮凝胶，由丹参酮粉，甲氧苄啶，维生素A，维生素E，丙二醇、月桂醇、尼泊金乙酯、乙醇、卡波姆凝胶组成。其制备工艺，包括以下步骤：按配方取乙二胺四乙酸二钠盐，加水使溶解后，加入卡波姆搅匀，静置12～24小时，得卡波姆凝胶；按配方取乙醇，丙二醇，卡必醇混匀，加入甲氧苄啶，丹参酮粉，月桂醇，尼泊金乙酯，维生素A和维生素E，搅拌后与卡波姆凝胶合并，用三乙醇胺调节pH值至5～7，搅匀，即得。本发明凝胶直接作用于病灶，对皮肤刺激较小，通透性好，涂抹后不影响患者外观，在不同地区的气温下稳定性好，不易变质。
Description
技术领域
本发明属于中西药凝胶制剂，特别涉及克痤隐酮凝胶及其制备工艺。
背景技术
痤疮是一种毛囊与皮脂腺的慢性炎症性皮肤病。发病率约占人口的20％～24％。好发病于青春期的男女，成年后男子也可发病。目前市场上治疗痤疮的克痤隐酮乳剂，酊剂对皮肤刺激较大，易结痂，有油腻感，通透性不好，涂抹后影响患者外观，且在不同地区的气温下稳定性不好，易变质。
发明内容
本发明的目的是提供一种对皮肤刺激较小，不易结痂，无油腻感，通透性好，易涂展，涂抹后不影响患者外观，且在不同地区的气温下稳定性好，不易变质的克痤隐酮凝胶。
克痤隐酮凝胶，由丹参酮粉，甲氧苄啶，维生素A，维生素E和辅料制成。
辅料是丙二醇、月桂醇、尼泊金乙酯、乙醇、卡波姆凝胶。
卡波姆凝胶组份和重量配比为：由卡波姆10～20，乙二胺四乙酸二钠盐0.08～0.2和相当于卡波姆6～8倍重量的水制成。
其1000重量份中，各组份的重量配比为：
丹参酮粉 1.2～1.7 甲氧苄啶 1.1～1.7 维生素A 1～4
维生素E 1～4 丙二醇 20～100 卡必醇 10～80
月桂醇 5～30 尼泊金乙酯 0.5～2
50％～98％乙醇 200～300 卡波姆 10～20
乙二胺四乙酸二钠盐 0.05～0.2
其余为水。
其1000重量份中，各组份的最佳重量配比为：
丹参酮粉 1.5 甲氧苄啶 1.5 维生素A 3 维生素E 3
丙二醇 80 卡必醇 50 月桂醇 20
尼泊金乙酯 1 95％乙醇 250
卡波姆 12 乙-胺四乙酸二钠盐 0.1
其余为水。
卡波姆的型号可选用卡波姆941，卡波姆940，卡波姆934。可选用的卡波姆最佳型号为卡波姆940。
克痤隐酮凝胶的制备工艺，包括以下步骤：按配方取乙二胺四乙酸二钠盐，加水使溶解后，加入卡波姆搅匀，静置12～24小时，得卡波姆凝胶；按配方取乙醇，丙二醇，卡必醇混匀，加入甲氧苄啶，丹参酮粉，月桂醇，尼泊金乙酯，维生素A和维生素E，搅拌使其溶解后与卡波姆凝胶合并，用三乙醇胺调节PH值至5～7，搅匀，即得。
在加入甲氧苄啶，丹参酮粉，月桂醇，尼泊金乙酯，维生素A和维生素E的过程中可加热进行。
本发明克痤隐酮凝胶，是在原来乳剂的配方基础上，改进成的一种新剂型，本发明凝胶涂抹在痤疮部位，直接作用于病灶，对皮肤刺激较小，通透性好，疗效大大提高，涂抹后不影响患者外观，在不同地区的气温下稳定性好，不易变质。
申请人对克痤隐酮凝胶做了稳定性实验，药效学实验和毒理学实验，证明了本发明药品稳定性好，疗效显著，无毒副作用，用药安全。
1.稳定性实验
模拟不同地区的气温，将本发明样品置40±1℃，25±3℃，5±2℃模拟不同地区的气温考察30天，结果，其稠度、酸碱度、色泽均匀无明显变化，亦无出现霉变现象。
2.药效学实验
“克痤隐酮凝胶”对实验性兔耳痤疮模型有较好的治疗作用，有明显减少毛囊角栓，减轻表皮增厚，减少真皮炎细胞浸润；有抑制大白鼠棉球肉芽肿的作用；对大白鼠角叉菜胶性足爪肿胀有一定的抑制作用；对二甲苯致小白鼠耳廓肿胀有较好的抑制作用；体外抗菌实验表明：克痤隐酮凝胶对痤疮丙酸杆菌有较强的抑制作用，对金黄色葡萄球菌亦有一定的抑制作用。
3.毒理学实验
(1)急性毒性实验
大白鼠完整皮肤和破损皮肤局部外涂克痤隐酮凝胶，最高浓度(人临床用浓度的33倍)24小时内给药三次，连续观察7天，未发现明显的毒性反应。
(2)皮肤刺激实验
家兔背部皮肤(完整皮肤和破损皮肤)一次外涂克痤隐酮凝胶(人临床用浓度的33倍)，对家兔皮肤无明显的刺激反应。
(3)皮肤过敏实验
外涂克痤隐酮凝胶，豚鼠未出现明显的皮肤和全身过敏反应。
(4)长期毒性实验
大白鼠皮肤外用3个月(6g和0.18g生物/kg，均分为完整皮肤组和破损皮肤组)，结果：各组动物无明显皮肤刺激反应。各组动物血液学、血液生化学指标均在正常范围，病理学检查重要脏器未见异常。
具体实施方式
实施例：
制成1000克克痤隐酮凝胶，称取丹参酮粉1.5克，甲氧苄啶1.5克，维生素A 3克，维生素E 3克，卡波姆940 12克，乙二胺四乙酸二钠盐0.1克，丙二醇80克，卡必醇50克，月桂醇20克，尼泊金乙酯1克，95％乙醇250克，水适量。包括以下步骤进行：
其一，按上述重量取乙二胺四乙酸二钠盐，加水使溶解后，加入卡波姆搅匀，静置12～24小时，得卡波姆凝胶。
其二，按上述重量取95％乙醇，丙二醇，卡必醇混匀，再加入甲氧苄啶，丹参酮粉，月桂醇，尼泊金乙酯，维生素A和维生素E，搅拌使溶解后，即得混合液。
最后，将混合液与卡波姆凝胶合并，用三乙醇胺调节PH值至5～7，搅匀，即得克痤隐酮凝胶。
Claims (4)
1、一种治疗痤疮的凝胶型药物组合物，其特征在于其1000重量份中，各组分重量配比为：
丹参酮粉 1.2～1.7 甲氧苄啶 1.1～1.7 维生素A 1～4
维生素E 1～4 丙二醇 20～100 卡必醇 10～80
月桂醇 5～30 尼泊金乙酯 0.5～2
50％～98％乙醇 200～300 卡波姆 10～20
乙二胺四乙酸二钠盐 0.05～0.2
其余为水。
2、根据权利要求1所述的组合物，其特征在于其1000重量份中，各组分和重量配比为：
丹参酮粉 1.5 甲氧苄啶 1.5 维生素A 3
维生素E 3 丙二醇 80 卡必醇 50
月桂醇 20 尼泊金乙酯 1
95％乙醇 250 卡波姆 12
乙二胺四乙酸二钠盐 0.1
其余为水。
3、根据权利要求2所述的组合物，其特征在于卡波姆的型号选用卡波姆941，卡波姆940或卡波姆934。
4、根据权利要求1所述的药物组合物的制备工艺，其特征在于包括以下步骤：按配方取乙二胺四乙酸二钠盐，加水溶解后，加入卡波姆搅匀，静置12～24小时，得卡波姆凝胶；按配方取乙醇，丙二醇，卡必醇混匀，加入甲氧苄啶，丹参酮粉，月桂醇，尼泊金乙酯，维生素A和维生素E，搅拌使其溶解后与卡波姆凝胶合并，用三乙醇胺调节PH值至5～7，搅匀，即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03132232 CN1221263C (zh) | 2003-07-30 | 2003-07-30 | 一种治疗痤疮的凝胶型药物组合物及其制备工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03132232 CN1221263C (zh) | 2003-07-30 | 2003-07-30 | 一种治疗痤疮的凝胶型药物组合物及其制备工艺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1483408A CN1483408A (zh) | 2004-03-24 |
| CN1221263C true CN1221263C (zh) | 2005-10-05 |
Family
ID=34154053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03132232 Expired - Lifetime CN1221263C (zh) | 2003-07-30 | 2003-07-30 | 一种治疗痤疮的凝胶型药物组合物及其制备工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1221263C (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816112B (zh) * | 2014-03-10 | 2016-11-09 | 吴争鸣 | 一种复方丹参凝胶剂的制备方法 |
| CN104288158B (zh) * | 2014-09-30 | 2017-01-11 | 江苏奇力康皮肤药业有限公司 | 一种含丹参酮的皮肤清洗液的制备方法 |
| CN108553608A (zh) * | 2018-05-30 | 2018-09-21 | 武汉润禾生物医药有限公司 | 一种治疗外阴皮炎瘙痒的抑菌凝胶及其制备方法 |
-
2003
- 2003-07-30 CN CN 03132232 patent/CN1221263C/zh not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1483408A (zh) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silva et al. | Natural medicaments in endodontics: a comparative study of the anti-inflammatory action | |
| US8008345B2 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| JP2005508936A (ja) | 抗刺激性酒さ治療 | |
| CN109431873B (zh) | 一种修复舒缓皮肤炎症的组合物 | |
| IT8024370A1 (it) | Composizione terapeutica di dimetil solfossido e procedimenti per il suo impiego | |
| US7074832B2 (en) | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use | |
| CN101773511B (zh) | 治疗痤疮的复方外用组合药物及其制备方法 | |
| JPH01503061A (ja) | 局所的メトロニダゾール製剤 | |
| JPH10507201A (ja) | 皮膚病及び皮膚障害の予防及び治療のためのレクチンを用いる方法 | |
| CN1221263C (zh) | 一种治疗痤疮的凝胶型药物组合物及其制备工艺 | |
| CN101485675B (zh) | 阿达帕林盐酸克林霉素复方凝胶制剂及其制备方法 | |
| CN1210041C (zh) | 治疗痤疮的复方外用药物 | |
| DE60219148T2 (de) | Pharmazeutische Zusammensetzung zur Verhinderung der Entwicklung und Progression von mykotischen Hautoberflächenerkrankungen | |
| RU2336877C1 (ru) | Местное антимикробное средство | |
| JPH0255404B2 (zh) | ||
| ROBINSON et al. | Tolnaftate, a potent topical antifungal agent | |
| CN1269476C (zh) | 维甲酸复合脂质体及其制备方法与应用 | |
| CN1528326A (zh) | 主治痤疮的复方外用药物 | |
| JP4018764B2 (ja) | 津液改善用皮膚外用剤 | |
| RU2295958C1 (ru) | Фармацевтический состав для лечения грибковых заболеваний и способ его получения | |
| CN102872158A (zh) | 一种治疗湿疹的外用药物组合物及其制备方法 | |
| CN1350862A (zh) | 治疗白癜风用组合物 | |
| RU2563811C1 (ru) | Фармацевтическая композиция для лечения грибковых заболеваний | |
| EP0086228A1 (en) | USE OF CARBAMIDE PEROXIDE FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING ACNE VULGARIS. | |
| JP2516477B2 (ja) | 皮膚の血行不良に起因する疾患の治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEFEI CUBE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TONG YUXIN Effective date: 20080222 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080222 Address after: 669 cubic Industrial Park, Changjiang West Road, Hefei, Anhui Patentee after: Hefei Lifeon Pharmaceutical Co.,Ltd. Address before: Bio pharmaceutical Park, hi tech Zone, 669 West Changjiang Road, Anhui, Hefei Patentee before: Tong Yuxin |
|
| C56 | Change in the name or address of the patentee |
Owner name: HEFEI LIFEON MEDICATION GROUP Free format text: FORMER NAME: LIFANG PHARMACEUTICAL MFG. CO, LTD, HEFEI |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 669 cubic Industrial Park, 230088 West Changjiang Road, Anhui, Hefei Patentee after: HEFEI LIFEON PHARMACEUTICAL Co.,Ltd. Address before: 669 cubic Industrial Park, 230088 West Changjiang Road, Anhui, Hefei Patentee before: Hefei Lifeon Pharmaceutical Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20051005 |
|
| CX01 | Expiry of patent term |